RECEIVED CENTRAL FAX CENTER

NO. 6878 P. 1/15

JUL 18 2005

PFC/SB/21 (09-04) Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE							
TRANSMITTAL FORM		required to respond to a plication Number	collection g	ection of information unless it displays a valid OMB control number.			
		Filing Date August 06					
		st Named Inventor		August 06, 2003			
		And the bit		Manfred SCHUDOK et al. 1624			
		aminer Name					
(to be used for all correspondence after Initial filing)				BALASUBRAMANIAN, V.			
Total Number of Pages in This Submission	15 Atti	orney Docket Numbe	DEA	V2000/A	043 US	NP 1	
ENCLOSURES (Check all that apply)							
Fee Transmittal Form	Transmittel Form Draw				After Allowance Communication to TC		
Fee Attached	Licens	sing-related Papers				al Communication to Board peals and interferences	
Amendment/Reply	Pelilio					el Communication to TC al Notice, Brief, Reply Brief)	
After Final	Provis	on to Convert to a sional Application			Prop	ietary Information	
Affidavits/declaration(s)		r of Attorney, Revoca se of Correspondence			Slatu	s Letler	
Extension of Time Request		nal Disclaimer				Enclosure(s) (please Identify	
lm ' l	Renue	est for Refund		٦	belov	<i>y</i> .	
Express Abandonmant Request	声 :						
Information Disclosure Statement		umber of CD(s)		-			
Conditional Common Parisons		endscape Table on	CD		_ــــ		
Certified Copy of Priority Document(s)	Remarks						
REPLY PURSUANT TO 37 C.F.R. § 1.111							
incomplete Application Reply to Missing Parts							
under 37 CFR 1,52 or 1.53							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name AVENTIS PHARMACEUTICALS INC.							
Signature Openh O. Rossi							
Printed name Joseph Rossi							
Date July 18, 2005	July 18, 2005 Reg. No. 47,03B						
CERTIFICATE OF TRANSMISSION/MAILING							
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Poetal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 15)							
Signature Benée Mitennis							
Typed or printed name Renee McGinnis					Date	July 18, 2005	

This odisction of information is required by 37 CFR 1.5. The information is required to obtain or ratain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or auggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Palent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

`JUL. 18. 2005 2:03PM

AVENTIS US PAT DEPT

RECEIVED

NO. 6878 P. 2/15

DEAV2000/A043 US NP1

JUL 1 8 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of SCHUDOK et al.

Examiner:

V. Balasubramanian

Art Unit:

1624

Application No.: 10/634,827

Filed:

August 6, 2003

Title:

MALONAMID AND MALONAMIC ESTER DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY, THEIR PREPARATION, AND THEIR

USE

TELEFAX CERTIFICATE
i hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

January 18, 2005 te of Transmission

René Missini

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

REPLY PURSUANT TO 37 C.F.R. § 1.111

In response to the Office Action dated April 18, 2005 ("the Action"), reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

- Amendments to the Disclosure begin on page 2 of this paper.
- Amendments to the Claims are reflected in the listing of the claims that begins on page 3 of this paper.
- Remarks/Arguments begin on page 13 of this paper.

DEAV2000/A043 US NP1

PATENT

Amendments to the Disclosure

Please add the following paragraph at page 1, line 1:

-This application is a divisional application of U.S. Patent Application Serial No. 09/965,790, filed October 1, 2001, now U.S. Patent No. 6,645,992, the entirety of which is incorporated herein by reference. --